UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S313-S314

2022

Volltextzugriff (PDF)

MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S311

2022

Volltextzugriff (PDF)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

Journal of scientific innovation in medicine, 2020-07, Vol.3 (3)

2020

Volltextzugriff (PDF)

How I Treat: Secondary Acute Myeloid Leukemia

Blood, 2024-10

2024

Volltextzugriff (PDF)

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure

Leukemia & lymphoma, 2019-07, Vol.60 (9), p.2207-2213

2019

Volltextzugriff (PDF)

Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis

Clinical lymphoma, myeloma and leukemia, 2024-08

2024

Volltextzugriff (PDF)

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

Expert opinion on pharmacotherapy, 2017-08, Vol.18 (12), p.1213-1224

2017

Volltextzugriff (PDF)

The serine threonine kinase RIP3: lost and found

BMB Reports, 2015, 48(6), , pp.303-312

2015

Volltextzugriff (PDF)

AML-032 Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S289-S289

2024

Volltextzugriff (PDF)

Beyond HMAs: Novel Targets and Therapeutic Approaches

Seminars in hematology, 2024-08

2024

Volltextzugriff (PDF)

AML-310: Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S303-S304

2021

Volltextzugriff (PDF)

MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S310

2022

Volltextzugriff (PDF)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome

Onkogematologii͡a, 2022-11, Vol.17 (4), p.106-117

2022

Volltextzugriff (PDF)

MDS-773 Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S406-S407

2024

Volltextzugriff (PDF)

MDS-531 Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S398-S398

2024

Volltextzugriff (PDF)

Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation

Transplantation and cellular therapy, 2024-08

2024

Volltextzugriff (PDF)

AML-266: Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S296-S296

2021

Volltextzugriff (PDF)

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Oncotarget, 2018-06, Vol.9 (45), p.27882-27894

2018

Volltextzugriff (PDF)

AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S306-S306

2023

Volltextzugriff (PDF)

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia

British journal of haematology, 2019-10, Vol.187 (2), p.e45-e48

2019

Volltextzugriff (PDF)

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Leukemia & lymphoma, 2022-06, Vol.63 (7), p.1660-1668

2022

Volltextzugriff (PDF)

Traitement des syndromes myélodysplasiques de haut risque

Bulletin du cancer, 2023-11, Vol.110 (11), p.1162-1167

Adès, Lionel

2023

Volltextzugriff (PDF)

Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes

Cancer treatment reviews, 2024-02, Vol.123, p.102673-102673, Article 102673

2024

Volltextzugriff (PDF)

MDS-112: A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S314-S315

2020

Volltextzugriff (PDF)

Changing frontline AML treatment patterns from 2013 to 2022

Leukemia research, 2023-09, Vol.132, p.107354-107354, Article 107354

2023

Volltextzugriff (PDF)

1 – 25 von 656

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(583)
Mit Volltextzugriff
(511)

Publikationsform

Artikel
(632)
Buchkapitel
(16)
Berichte
(6)
Bücher
(2)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(539)
Life Sciences & Biomedicine
(537)
Hypomethylating Agents
(465)
Humans
(341)
Hematology
(312)
Oncology
(309)
Acute Myeloid Leukemia
(237)
Myelodysplastic Syndromes
(172)
Myelodysplastic Syndrome
(140)
Hypomethylating Agent
(135)
Myelodysplastic Syndromes - Drug Therapy
(134)
Leukemia
(126)
Aged
(123)
Azacitidine
(123)
Decitabine
(121)
Leukemia, Myeloid, Acute - Drug Therapy
(111)
Azacitidine - Therapeutic Use
(106)
Male
(104)
Chemotherapy
(103)
Female
(102)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Lymphoma, Myeloma And Leukemia
(62)
Leukemia Research
(42)
Leukemia & Lymphoma
(31)
Annals Of Hematology
(22)
British Journal Of Haematology
(22)
Expert Review Of Hematology
(22)
Biology Of Blood And Marrow Transplantation
(16)
Cancer
(16)
Frontiers In Oncology
(16)
Cancers
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes

MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

How I Treat: Secondary Acute Myeloid Leukemia

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure

Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

The serine threonine kinase RIP3: lost and found

AML-032 Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience

Beyond HMAs: Novel Targets and Therapeutic Approaches

AML-310: Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine

MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome

MDS-773 Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

MDS-531 Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model

Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation

AML-266: Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Traitement des syndromes myélodysplasiques de haut risque

Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes

MDS-112: A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent

Changing frontline AML treatment patterns from 2013 to 2022

Suchergebnisse filtern